Implementing the Rare Diseases Action Plan: learnings from amyloidosis care
Networked models of care have the potential to provide better access to specialist care for rare diseases in the NHS. The government committed to establishing an innovative networked model of care for amyloidosis in the England Rare Diseases Action Plan 2024.1 Successful roll-out could address inequities in care for amyloidosis ...
From long-term vision to in-year savings: digital solutions for today’s NHS
Digitally enabling solutions must deliver (in-year) cost savings as well as show demonstrable value in driving up productivity across the NHS
Tackling health inequalities through people-led projects
Novartis Pharmaceuticals UK Ltd has provided sponsorship funding for this non-promotional piece. Novartis has had no input into the content, aside from agreement on the topic (tackling health inequalities through people-led projects).
From data to delivery: Why investing in personalised care is critical for system efficiency and health equity
For senior NHS leaders, addressing health inequalities is no longer just a moral imperative; it is a clinical and financial necessity
Transforming diagnostics for Somerset: Bridgwater CDC progresses at speed
As part of a long-term managed equipment service partnership with Somerset Foundation Trust, Ergéa has supported the development of the new £17.8m Bridgwater Community Diagnostic Centre (CDC), which will transform access to care in Bridgwater and across Somerset.
Reimagining the Interstitial Lung Disease (ILD) Care Pathway - Boehringer Ingelheim article
Interstitial lung disease (ILD) describes more than 200 rare and complex lung conditions. The most common fibrotic ILD is idiopathic pulmonary fibrosis (IPF), which has a median untreated life expectancy of just three to five years from diagnosis.[1] This makes timely and accurate identification, as well as rapid referral for ...
We digitised decisions. Now we must digitise delivery.
The NHS holds more clinical data than ever, yet patient flow remains a daily struggle. Not because digital transformation has failed – but because we digitised decisions while leaving delivery analogue.
What can ctDNA tell us about a patient’s cancer?
Circulating tumour DNA (ctDNA) is transforming how we diagnose and treat complex cancers, particularly when clinical pathways are constrained by the speed, safety, and limitations of tissue biopsy.
Dementia diagnosis: why patients can’t wait for the future
The government’s new vision for dementia diagnosis is ambitious: by 2029, more than 92 per cent of patients could receive a diagnosis within 18 weeks of referral, up from fewer than half today.
Getting classification right: Why remote monitoring safety depends on using the right level of medical device assurance
Remote monitoring has become an essential component of virtual wards and community-based care. As adoption accelerates, understanding medical-device classification is not a legal technicality, but a matter of clinical safety, governance and system integrity.